From January 2026, patients in Czechia with severe depression or other serious mental health conditions may be able to receive psilocybin therapy, the active ingredient in magic mushrooms, under strict medical supervision. The Ministry of Health has finalized a decree specifying how the treatment can be used, following a Senate-approved amendment to legalize medical psilocybin earlier this year. The therapy is intended for patients whose symptoms have not responded to conventional treatments such as antidepressants. Outgoing Health Minister Vlastimil Válek confirmed it will also be available for cancer-related depression and sudden worsening of other serious neuropsychiatric conditions, provided its use is backed by scientific evidence. The decree limits prescribing and dosing: only psychiatrists can administer psilocybin, treatments must be supervised by specialists, and patients can receive a maximum of three doses per month, with no more than 75 grams in total. A single dose cannot exceed 35 mg or 0.4 mg per kilogram of body weight. Authorities say psilocybin is low in toxicity, non-addictive, and generally safe under medical supervision, though unsupervised use can be dangerous. Dr. Rita Kočárová, a psychologist and researcher in psychedelic care, emphasizes that legal approval alone is not enough. “Treatment with psychedelics requires expertise, a... The post Czechia Approves Regulations For Medical Use Of Psilocybin appeared first on Prague Morning .